An eight-day bench hearing held in Minneapolis, Minn., in December 2009, could have far-reaching legal implications for antitrust law, particularly regarding future pharmaceutical cases. It could set a precedent making it...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: